Ghent University Academic Bibliography

Advanced

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase ha, open-label study

Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe UGent, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar and Goedele De Smedt (2012) JOURNAL OF HEPATOLOGY. 56(6). p.1247-1253
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
Antiviral, Genotype, Monotherapy, HEPATITIS-C VIRUS, PEGINTERFERON PLUS RIBAVIRIN, RANDOMIZED-TRIAL, INITIAL TREATMENT, DRUG-USERS, EAST, COMBINATION, PREVALENCE, MANAGEMENT, ALPHA-2A, TMC435, HCV
journal title
JOURNAL OF HEPATOLOGY
J. Hepatol.
volume
56
issue
6
pages
1247 - 1253
Web of Science type
Article
Web of Science id
000304512300007
JCR category
GASTROENTEROLOGY & HEPATOLOGY
JCR impact factor
9.858 (2012)
JCR rank
5/73 (2012)
JCR quartile
1 (2012)
ISSN
0168-8278
DOI
10.1016/j.jhep.2011.12.033
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2915697
handle
http://hdl.handle.net/1854/LU-2915697
date created
2012-06-22 11:49:48
date last changed
2016-12-19 15:46:22
@article{2915697,
  author       = {Moreno, Christophe and Berg, Thomas and Tanwandee, Tawesak and Thongsawat, Satawat and Van Vlierberghe, Hans and Zeuzem, Stefan and Lenz, Oliver and Peeters, Monika and Sekar, Vanitha and De Smedt, Goedele},
  issn         = {0168-8278},
  journal      = {JOURNAL OF HEPATOLOGY},
  keyword      = {Antiviral,Genotype,Monotherapy,HEPATITIS-C VIRUS,PEGINTERFERON PLUS RIBAVIRIN,RANDOMIZED-TRIAL,INITIAL TREATMENT,DRUG-USERS,EAST,COMBINATION,PREVALENCE,MANAGEMENT,ALPHA-2A,TMC435,HCV},
  language     = {eng},
  number       = {6},
  pages        = {1247--1253},
  title        = {Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase ha, open-label study},
  url          = {http://dx.doi.org/10.1016/j.jhep.2011.12.033},
  volume       = {56},
  year         = {2012},
}

Chicago
Moreno, Christophe, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, and Goedele De Smedt. 2012. “Antiviral Activity of TMC435 Monotherapy in Patients Infected with HCV Genotypes 2-6: TMC435-C202, a Phase Ha, Open-label Study.” Journal of Hepatology 56 (6): 1247–1253.
APA
Moreno, C., Berg, T., Tanwandee, T., Thongsawat, S., Van Vlierberghe, H., Zeuzem, S., Lenz, O., et al. (2012). Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase ha, open-label study. JOURNAL OF HEPATOLOGY, 56(6), 1247–1253.
Vancouver
1.
Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase ha, open-label study. JOURNAL OF HEPATOLOGY. 2012;56(6):1247–53.
MLA
Moreno, Christophe, Thomas Berg, Tawesak Tanwandee, et al. “Antiviral Activity of TMC435 Monotherapy in Patients Infected with HCV Genotypes 2-6: TMC435-C202, a Phase Ha, Open-label Study.” JOURNAL OF HEPATOLOGY 56.6 (2012): 1247–1253. Print.